Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL18042462 | 1.00 | KMT2A (0.64) | KMT2AGGPS1MAPTALDH1A1MEN1 | |
| Phosphoric Acid SCHEMBL16655450 | 1.00 | KMT2A (0.64) | KMT2AGGPS1MAPTALDH1A1MEN1 | |
| Squalene SCHEMBL27769242 | 0.91 | KMT2A (0.77) | KMT2AGGPS1MAPTALDH1A1MEN1 | |
| Squalene SCHEMBL27745351 | 0.91 | KMT2A (0.77) | KMT2AGGPS1MAPTALDH1A1MEN1 | |
| Squalene SCHEMBL28409601 | 0.91 | KMT2A (0.77) | KMT2AGGPS1MAPTALDH1A1MEN1 | |
| Squalene SCHEMBL27745343 | 0.91 | KMT2A (0.77) | KMT2AGGPS1MAPTALDH1A1MEN1 | |
| SCHEMBL6716175 | 0.89 | KMT2A (0.80) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL3092587 | 0.89 | KMT2A (0.80) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL12713311 | 0.89 | KMT2A (0.80) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL3090339 | 0.89 | KMT2A (0.80) | KMT2AMAPTALDH1A1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-7763429-B2 | Compound containing farnesyl diphosphate for modulating TRPV3 function and use thereof | KOREA UNIVERSITY INDUSTRY AND ACADEMIC COLLABORATION FOUNDATION (KR) | 2010-07-27 | — | — | US | disclosed |
| US-20100136533-A1 | COMPOUND CONTAINING FARNESYL DIPHOSPHATE FOR MODULATING TRPV3 FUNCTION AND USE THEREOF | KOREA UNIVERSITY INDUSTRY AND ACADEMIC COLLABORATION FOUNDATION (KR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | KMT2A 2963/4885GGPS1 956/4885MAPT 898/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | KMT2A 2963/4885GGPS1 956/4885MAPT 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.